SightfileU.S. market data from official filings

INHIBRX BIOSCIENCES INC (INBX)

Name: INHIBRX BIOSCIENCES INC (INBX) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0002007919 · EDGAR filings · Updated 2026-07-16

INHIBRX BIOSCIENCES INC (INBX) has reported institutional ownership of 87.0%, with 135 institutional managers holding positions valued at $854.6M per the latest 13F reporting period.

Institutional ownership

87.0%

Institutional managers

135

Reported 13F value

$854.6M

Insider activity

3 trans.

−$11.3M net selling

Latest updates

2026-07-16 — Current report (8-K) filed
2026-06-15 — Current report (8-K) filed
2026-06-04 — Insider transaction reported (Form 4)
2026-06-04 — Insider transaction reported (Form 4)
2026-06-04 — Insider transaction reported (Form 4)
2026-06-04 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, INHIBRX BIOSCIENCES INC has 135 institutional holders and institutional ownership of 87.0%.

Insider activity

Insiders reported 3 transactions (0 buys, 3 sells) across 1 reporting insiders, with a net reported value of −$11.3M.

Related companies

CYTOMX THERAPEUTICS INC. (CTMX) · BILLIONTOONE INC (BLLN) · ANNEXON (ANNX) · SONIDA SENIOR LIVING INC (SNDA) · UROGEN PHARMA LTD (URGN) · JANUX THERAPEUTICS INC (JANX)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-16.